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Abstract
Purpose This paper explores the feasibility of a new therapy for the treatment of hypospadias patients. Hypospadias is a very 
common congenital malformation of male genitals, with very high rate of recurrences after surgery. The field of regenerative 
medicine, which offers innovative solutions for many pathologies, still does not offer reliable solution for this pathology. 
Here, we propose quality, safety, and clinical feasibility assessment for an oral mucosa advanced therapy medicinal product 
(ATMP) grown on a biocompatible scaffold for a clinical study on urethral reconstruction of hypospadias patients.
Methods Urethral and oral mucosal epithelia from donor biopsies were cultivated between two fibrin layers, under clinical-
grade conditions for cell and tissue characterization and comparison, aimed at tissue engineering. In addition, single-clone 
analyses were performed to analyze gene expression profiles of the two epithelia by microarray technology.
Results Oral mucosa appeared suitable for urethral reconstruction. The resulting ATMP was proven to maintain stem cells 
and regenerative potency. The preclinical safety studies were performed on human tissues to assess abnormalities and tumo-
rigenicity, and confirmed the safety of the ATMP. Finally, the patient selection and the clinical protocol for the upcoming 
clinical trial were defined.
Conclusions Against this backdrop, in this paper, we are proposing a new reproducible and reliable ATMP for the treatment 
of hypospadias.
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Abbreviations
MO  Human oral mucosa keratinocytes
UK  Human urethra keratinocytes
CFE  Colony forming efficiency
DP  Final product
K  Cytokeratin
ATMP  Advanced therapy medicinal product
QFQ  Q band by fluorescence and quinacrine
Introduction
Hypospadias, one of the most common congenital malfor-
mations of male genitals with an incidence of 1 out of 1000 
male births (Orphanet 440), is defined by an abortive devel-
opment of the urethral corpus spongiosum, ventral prepuce, 
and arrest in the normal embryological development of the 
urethra [1]. Problems related to this disease include altered 
urination and ejaculation and psychological problems caus-
ing depression and disability. Foreskin is frequently used for 
one-stage urethral reconstruction, but it only provides one 
chance for application, and due to the high rate of treatment 
failure, skin flaps must later be removed from different body 
sites, with side effects such as hair growth inside the urethra, 
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tissue retraction, and infection [2]. Oral mucosa tissue has 
been used in different surgical practices such as pharyngeal 
[3], maxillofacial [4], reconstructive vaginal surgeries [5], 
and urethral reconstruction. This is due to easy access to the 
donor site and its high regenerative capacity, as oral mucosa 
reacts to daily damage at its original anatomical site. In cases 
of large removal, as needed for hypospadias treatment, 
patients report pain, altered salivary function, a morbidity 
rate of 3–4% at the donor site [6], and scars and oral contrac-
tures in about 20% of cases [7]. Mechanical irritation from 
dental rubbing and parafunctional biting of the oral mucosa 
increases the chances of oral cancer development [8]. This 
practice only allows two big tissue removals from the oral 
mucosa, but the aforementioned procedures require repeated 
surgery in approximately half of the patients [9]. ATMPs, 
such as somatic cell therapy or tissue-engineered products, 
can enable tissue regeneration starting from a small biopsy. 
When supplied with stem cells, the resulting cultured tissue 
can engraft and persist at the desired location, self-renewing 
over the lifetime and restoring missing functionality [10].
Here, we planned a tissue-engineering-based clinical trial 
to (1) identify and characterize the cells able to restore the 
tissue in vitro and in vivo and (2) to select the appropriate 
biomaterials, “clinical-grade” culture medium, and controls 
for the different phases of the manufacturing process.
As requested by regulatory authorities, the cultured 
tissue was characterized by identity, purity, potency, and 
safety on in vitro models [11]. Under these conditions, the 
transplanted tissue can safely grow within the surrounding 
environment.
The pig animal model originally selected for preclinical 
studies revealed different sensitivities to these culture con-
ditions compared to human cells, making it unsuitable for 
safety analysis. Alternatively, we performed preclinical tests 
in vitro using human cells. This process included the com-
parison of cultured urethra and oral mucosa to determine 
whether human oral mucosa keratinocytes (MO) could be 




Samples were obtained in accordance with the Declara-
tion of Helsinki, and informed consent was obtained from 
donors. Small oral mucosa biopsy samples (0.25 cm2) were 
obtained from the inner cheek of patients undergoing sur-
gery for urethral stricture treatment.
Urethra samples were obtained either from patients 
undergoing sexual transition surgery (healthy) or stricture 
treatment surgery (pathologic).
Cell culture and CFE
UK and MO were cultured and controlled as described [10, 
table 4 in 12].
Growth factor dependence assay
An aliquot of final Product (DP) was dissociated using 2 U/
ml Dispase II at 37 °C for 15 min, followed by 0.05% trypsin 
and 0.01% EDTA at 37 °C for 10 min, and then plated in the 
absence of growth factors as described (Suppl. Mat.).
Soft agar assay
Keratinocytes obtained from DP were collected and seeded in 
a semisolid agar medium using the CytoSelect™ 96-Well Cell 
Transformation Assay Kit (Cell Biolabs, Inc.; Suppl. Mat.).
Karyotype analysis
After DP dissociation, MO were cultivated up to sub-conflu-
ence and shipped to the Medical genetics’ laboratory of Mod-
ena Policlinic Hospital for karyotype analysis and Q band by 
fluorescence and quinacrine (QFQ) staining.
Immunofluorescence
Cultured epithelial cells were trypsinized, centrifuged, and 
fixed. Cytospins were permeabilized, blocked, incubated with 
anti-p63 (Ventana) or anti-BMI-1 (Cell Signaling) primary 
antibodies.
A portion of the cytospins was double-stained for anti-
mouse Vimentin antibody (BioLegend) and anti-wide spec-
trum Cytokeratin antibody (AbCam) for the identity and purity 
assays.
Cells cultured on glass coverslips were fixed, permeabi-
lized, and incubated with anti-K6 (AbCam), anti-K7 (Progen), 
anti-K8 (Progen), or anti-K18 (AbCam) primary antibodies.
Human tissues were embedded in an optimal cutting tem-
perature (OCT) compound, frozen, and cut into 5–7 mm 
sections on a cryostat. The sections were then, fixed, perme-
abilized, blocked, and incubated with anti-K6, anti-K7, anti-
Bmi1, anti-p63-α (PRIMM), or anti- K8 & K18 (Cell Marque) 
primary antibodies.
Nuclei were labeled with 4′,6-diamidino-2-phenylindole 
(DAPI). Further information in Suppl. Mat.
Microarray analysis
Stem-cell clones from sub-confluent primary cultures of 
oral mucosae (n = 2) and urethras (n = 2) were obtained 
to perform clonal analyses as previously described [13]. 
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Subcultures from each clone were feeder-depleted using 
immunomagnetic beads (Miltenyi) and collected for RNA 
extraction and microarray analysis using HG-U133 Plus 2.0 
Array (Affimetrix).
Differentially Expressed Genes (DEGs) were selected 
from Robust Multi-array Average-normalized data through 
a supervised analysis, using the ANOVA module supplied 
by the Partek GS. 6.6 Software Package (http://www.parte 
k.com). The selected probe sets displayed a fold change con-
trast ≥ 2 and a false discovery rate ≤ 0.05 for DEGs in oral 
mucosa versus urethral clones. Upstream regulators were 
computationally predicted using the  Ingenuity® Pathway 
Analysis software  (IPA®, QIAGEN Redwood City, http://
www.qiage n.com/ingen uity).
Results
In vitro reconstruction of oral mucosal and urethral 
epithelium
The biopsies were surgically removed from oral mucosa 
and/or penile urethra of the patients, were placed in pri-
mary containers with transport medium, and transferred to 
the laboratory within 24 h. Different tissues were derived 
from each biopsy, as described above. The culture conditions 
were modified according to regulatory requests for similar 
products and included clinical-grade hormones and growth 
factors. Reagents were extensively screened for the absence 
of contaminants and cytotoxic effects, and the serum was 
also irradiated. The final tissue constructs consisted of modi-
fied fibrin glue scaffolds (EP Patent 1451302) covered by 
adhering ex vivo expanded autologous human epithelia. The 
cultured tissue was a 30–35 cm2 epithelial cell sheet contain-
ing oral stem cells, instrumental for the long-term regenera-
tion of healthy, functional, and self-renewing epithelium. To 
reduce friction forces over the epithelium during and after 
surgery, the constructs were further covered with a differ-
ent formulation of fibrin glue, easily resorbable (patent in 
preparation).
Oral mucosa vs. urethral epithelium in vivo 
and in vitro
Cytokeratins (K) expression is characteristic of epithelia, as 
they are part of the cytoskeleton and critical for the integrity 
and mechanical stability of cells and tissue as well as for cell 
function regulation. Indeed, some cytokeratins are involved 
in intracellular protection from stress, or wound healing, and 
apoptosis. Here, some of them were characterized in oral 
mucosal and urethral epithelia to investigate tissue-specific 
modulation in vivo and in vitro under mitogenic stimuli in 
the defined culture conditions. As shown in Fig. 1a, the two 
epithelia revealed very similar expression patterns, both 
in vivo and in vitro. K6, constitutively expressed in highly 
proliferative mucosae, was shown in both tissues in vivo 
and in vitro. The K18 primary epithelial keratin was acti-
vated in vitro, as it may change in reactive conditions [14], 
in both urethra and oral mucosa. K8, typically expressed 
in oral malignancies, was negative in oral mucosa in vivo 
and in vitro [15]. K7 exhibited a different expression in vivo 
and in vitro, as cultured cells exposed to mitogenic stimuli 
behave like cells in wound healing, and several functions are 
subsequently activated [14, 16]. Altogether, the cytokeratin 
expression maintained a physiologic tissue- and differentia-
tion-specific location and regulation pattern, comparable in 
urethra and oral mucosa.
Clonogenic potential
To assess the in  vitro maintenance of tissue regenera-
tive capacity, we considered: (i) the clonogenic potential, 
namely, the single-cell capacity to reconstitute the whole tis-
sue; (ii) the comparative abundance of stem, progenitor, and 
transient-amplifying cells; and (iii) related marker expres-
sion, to identify subpopulations in culture.
Epithelial cells were isolated from 50 oral mucosae and 
13 urethra biopsies from living donors, cultured using the 
same procedures described above. UK and MO had com-
parable clonogenic ability, respectively 7.2% ± 3.2 and 
2.1% ± 1.9. After the primary culture, the colony-forming 
efficiencies of the two epithelia were still similar, show-
ing a clonogenicity of 54.2% ± 14 in urethra cells and 
52.7% ± 29.9 in oral mucosa cells (Fig. 1b). This clonogenic 
potential was maintained for several passages, and then 
progressively decreased until replicative senescence was 
reached. The end of proliferation occurred after an average 
of 88 cell doublings for oral mucosa (N = 5), 167 for healthy 
(N = 4), and 80 for affected urethras [17], respectively, prov-
ing the absence of any immortalization events (S1).
Stem, progenitor, and transient‑amplifying cells
The proliferative compartment of lining epithelia is located 
in the basal layer and contains the three types of keratino-
cytes with different capacities for multiplication, holoclones, 
meroclones, and paraclones previously identified [13] and 
equally maintained after culturing oral mucosa and urethral 
epithelium under these “clinical-grade” conditions. Stem-
cell clones (holoclones) appeared in a lower amount in 
urethra than in oral mucosa [17]. To evaluate differences 
between the two epithelia, the respective populations of stem 
cells were further investigated by microarray transcriptome 
analysis.
The gene expression profiles of 15 holoclones isolated 
from 2 strains of oral mucosa, and 4 holoclones from 2 
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strains of urethra were analyzed by microarray. 100 differen-
tially expressed genes (DEGs) were identified in oral mucosa 
vs. urothelial holoclones (S2).
Based on the list of DEGs and according to current 
knowledge,  IPA® upstream regulator analysis proposed 
transcriptional regulators that could underlie the differen-
tial gene expression of oral mucosa and urethra holoclones.
Interestingly, the activation of BMI1 was predicted to 
be responsible for the transcriptional repression of HOXA 
genes [18, 19] that were indeed, downregulated in oral 
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mucosa vs. urethra holoclones. In addition, IPA high-
lighted the increased activity of TP63 in oral mucosa vs. 
urethra holoclones based on the modulation of its target 
genes (Fig. 1d).
The downregulation of HOX genes was partially con-
firmed in oral mucosa vs. urethra holoclones by a concurrent 
inhibition of KAT6A—i.e., MOZ, the catalytic subunit of a 
complex involved in the epigenetic regulation of HOX genes 
expression [19]—by KMT2A, an epigenetic transcriptional 
activator important for maintaining the expression of HOX 
genes, and by MEIS1, an HOX cofactor that promotes the 
transcription of HOX genes [20, 21].
The repression of HOX genes has been shown to preserve 
the undifferentiated state of stem cells [18] and these find-
ings are consistent with the maintenance of stem cells in 
culture, as well as their higher content in oral mucosa than 
urethra. Finally, cyclooxygenase 2 appeared to be down-
regulated in MO, compared to urethra, where it increases in 
urethral strictures [22] and squamous cell carcinoma.
At protein level, no significant differences were detected 
in single cells for p63 and BMI1, highly expressed in holo-
clones [17]. The differential gene expression in clones could 
reflect a difference in the capacity for stem-cell maintenance 
of oral mucosa vs. urethra after cell expansion. BMI1 and 
p63’s role in stem-cell function is also highlighted by their 
downregulation in progenitor and transient-amplifying cells, 
where loss of proliferative potential is associated with a 
reduced/null level of BMI1 and p63.
Altogether, these data suggest that BMI1 and p63 markers 
are related to regenerative properties needed for this treat-
ment and have no significant differences between tissues 
except for a moderate advantage for oral mucosa.
Manufacturing process: quality assessment
Since ATMPs are subjected to an extensive assessment by 
the regulatory authorities, we considered the requirements 
for quality, safety, and efficacy, so that patients and practi-
tioners can have high confidence in the product. We sum-
marized the quality as follows.
Identity and purity of the cell culture
The cell identity was controlled during cell production and 
banking, and we confirmed that no segregation, major cross 
contamination, or 3T3 cell fusion could arise during manip-
ulation in culture. The maintenance of cell identity was eval-
uated through positive and negative markers: keratins were 
constitutively expressed by oral mucosal cells, while murine 
vimentin is not produced by human epithelium, but was pre-
sent in residual feeder cells only (Fig. 1e). The identity and 
the purity of the cell population were routinely identified by 
human pankeratin + and mouse vimentin + cells, excluding 
the presence of other unexpected contaminants in culture.
Potency
Potency measures the relevant biological function(s) of the 
tissue that are possibly related to clinical efficacy.
Maintenance and regeneration of the tissue over time rely 
on the presence of stem cells in self-renewing tissues such 
as epithelia. Thus, markers related to regeneration and pro-
liferation of the oral mucosal stem cells were considered to 
be good candidate potency markers.
Accordingly, the product potency was evaluated by P63 
and BMI1 expression in the cell nuclei (Fig. 1e). These tran-
scription factors are related to the long-term capacity for 
proliferation and self-renewal in several cell types [23, 24], 
and oral mucosal stem cells (holoclones) maintain high lev-
els of P63, unlike transient-amplifying clones (paraclones). 
This marker’s expression decreases with replicative senes-
cence and disappears with differentiation [17, 25].
Preclinical studies
Tests on the animal model
Traditional drugs are characterized by preclinical studies 
in vivo to evaluate toxicity, pharmacodynamics, and pharma-
cokinetics. It is not possible to perform these tests on ATMP 
such as the cultured oral mucosa. The pig is considered a 
common model for several studies about the digestive [26] 
and the cardiovascular system, and is also highly analogous 
to humans at a genomic level [27]. Therefore, we selected 
swine as a suitable animal model to test the safety and the 
efficacy of our treatment. The use of a xenograft transplant 
Fig. 1  a Evaluation of cytokeratins expression of in  vitro (I) and 
in vivo (II) in oral mucosa and urethral samples; scale bar 50 µm. b 
Comparison between biopsy and primary culture clonogenicity of 
oral mucosa (N = 50) and urethral epithelium (N = 13). The corre-
sponding colony-forming efficiencies show a clonogenicity of 2.1% 
and 52.7% from biopsy and cultured oral mucosa, 7.2% and 54.2% 
from biopsy, and cultured urethra epithelium, respectively. c Percent-
age of clone developments from human (dark grey) and porcine (light 
grey) urethral biopsies and tissue cultures. The number of porcine 
clonogenic cells did not increase under these culture conditions. d 
Upstream regulators analysis results.  IPA® software upstream regula-
tors analysis predicted the transcriptional regulators that can underlay 
the different gene expressions detected between the holoclones from 
oral mucosa and those from urethra. BMI1 and TP63 were predicted 
to be activated, while KAT6A (i.e. MOZ), KMT2A, and MEIS1 were 
predicted to be inhibited in oral mucosa versus urethral holoclones. 
e Quality parameters and process controls defined by marker expres-
sion in vitro after culture: human pan-keratins staining (red) as con-
trol of epithelial cell identity and mouse vimentin (green) staining, 
as marker of process-related impurities by complementary number 
of human cells in  vitro (I, II); P63 and BMI1 staining (green), for 
potency measure on in vivo cryosection (I) and on the Drug Product 
(scale bar 50 µm) (II). All the cells nuclei were counterstained with 
DAPI (blue)
◂
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on the animal model would trigger an immune response, 
requiring the co-administration of immunosuppressive ther-
apy to prevent graft rejection. This practice is not representa-
tive of the clinical situation, since immunosuppressive drugs 
would alter the environment and cell survival, compromising 
the product’s efficacy. On this basis, we cultured urethral 
porcine epithelia in our “clinical-grade” culture conditions 
to transplant the porcine cells onto a pig to mimic human 
treatment. Three different porcine biopsies showed a cell 
yield and clonogenic capacity comparable to human biopsies 
(Fig. 1c).
However, a wide divergence was observed in the sub-
sequent cell expansion, and porcine cells revealed low 
responsiveness to culture conditions and mitogenic stimuli, 
maintaining a very low clonogenic capacity (4.1% ± 1,6) 
compared to human cells, which had a colony-forming effi-
ciency (CFE) of 54.2% ± 14. This divergent reaction to the 
culture conditions made the porcine model useless for safety 
studies, and therefore, its application was discontinued.
Thus, safety tests were performed on cultured cells as 
previously described [17], including soft agar colony forma-
tion assay to confirm the anchorage-dependent cell growth 
in vitro, growth factor dependence assay to predict uncon-
trolled cell growth, and finally, karyotype analysis of cul-
tured cells. Data confirmed the absence of any abnormalities 
under the selected culture conditions (S3).
The treatment and ancillary products
This phase I trial was designed to demonstrate in-human 
safety at 7–60 days after transplantation, then efficacy and 
safety from 3 months to 1 year (short-term efficacy) and 
up to 6 years (long-term efficacy) after the first treatment. 
The administration of this construct will follow the surgical 
resection of scars in patients suffering from symptoms due 
to hypospadias treatment failure. All ancillary materials for 
surgery, as anesthetics, lubricants, bandages, etc., were pre-
viously tested for toxicity on epithelia, since they are critical 
for the engraftment of cultured tissues [28].
Patient selection
The clinical trial (EudraCT number 2017-000361-78) will 
involve male pediatric and adult patients suffering from 
reduced urethral functionality and/or distal and recurrent 
lesions in a very large part of urethra due to failure of pri-
mary hypospadias repair. Patients included will be divided 
into two groups, 12 months–12 years and 14–65 years, with 
a clinical history of the previous primary hypospadias repair 
during pediatric age, presenting recurrent obstructive or 
irritating symptoms (frequent day/night urination and burn-
ing) and recurrent Urinary Tract Infections (UTIs; fever) or 
epididymitis (fever, scrotal pain and edema, high residual 
urine volume > 100 cc). The following clinical parameters 
will also be considered:
– Maximum flow rate determined by urof lowme-
try < 12 ml/s.
– Residual bladder urine > 100 cc.
– Evidence of penile urethra narrowing upon retrograde 
and voiding cystourethrography.
– Urethral meatus or fossa navicularis with caliber < 12 F.
Candidates for reconstructive urethroplasty by two-
stage procedure to repair penile urethral stricture, related 
to a failed primary hypospadias treatment, will be selected 
based on need according to the clinical features described 
above. They should display a cooperative attitude follow-
ing the study procedures, and they will be closely moni-
tored throughout the trial, and evaluated by the investigator 
according to the Investigator brochure specifications. Briefly, 
success will be assessed by the presence and stability of 
the urethral canal, with no significant stenosis impairing the 
urinary function (see above). The take of the ATMP in the 
urethra will be evaluated at 1 week and up to 1 month after 
the first surgery on the open wound bed, by visual inspec-
tion and quantification of the epithelium engraftment; in the 
second step, urethra will be tubularized and the maintenance 
of a pervious canal will be assessed by endoscopy at 1, 2, 
and up to 5 year follow-up.
Histology and molecular markers will be investigated on 
a small biopsy of the treated area, obtained from compliant 
patients to further confirm whether the tissue derives from 
urethra, foreskin, or oral mucosa.
The trial will be conducted in compliance with the Dec-
laration of Helsinki, current Good Clinical Practice, and all 
other applicable laws and regulations.
In summary, based on the previous clinical experience 
and scientific data, the expected therapeutic value combined 
with the safety profile of this procedure, provide an accept-
able overall risk/benefit assessment for the proposed trial.
Discussion
Urethral reconstruction to address failed hypospadias repair 
has attracted considerable interest in the last decades, but 
has generated variable positive and negative outcomes [29]. 
The use of autologous oral mucosa tissue was thought to 
be preferable, as it avoids some complications, but doubts 
remained about whether the heterotopic application could 
efficiently mimic urethral tissue, or would instead result in 
adverse reactions. In this study, we first evaluated the oral 
mucosa as urethral substitute at cellular and molecular level, 
and then defined a standardized protocol to combine these 
cells between a double fibrin scaffold in a tissue-engineered 
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construct. Fibrin is a natural substrate in wound healing and 
is rapidly reabsorbed on the lesion, allowing the epithelium 
engraftment [30]. The double fibrin scaffold provides protec-
tion during transport and surgical manipulations; in addition, 
it enables continuous adhesion, preserving the proliferative 
potential of epithelia. Indeed, this construct was proven to 
provide a normal stratified epithelium populated by the long 
living stem cells of the tissue.
We addressed the potential problems of a future clinical 
trial by developing a GMP/clinical-grade method for deriv-
ing a functional oral mucosa construct, along with standards 
for safety evaluation and quality control assays. The analyses 
of different proteins and cell behavior confirmed that the 
tissues under investigation were comparable and undergo 
physiological senescence, providing safety reassurances.
The protocol promotes a remarkable cell expansion from 
a very small biopsy, enabling a clinical performance similar 
to other regenerative medicine applications. The mainte-
nance of epithelial stem cells is highly relevant for wound 
healing and instrumental for long-term tissue renewal. Here, 
we provided two possible potency markers for their identifi-
cation: p63 and BMI1. Many evidences support their role as 
epithelial stem-cell markers, as p63 KO mice revealed the 
disappearance of epithelial linings, and BMI1 mediated the 
extension of oral mucosa life span and was able to repress 
INK4A/ARF-encoded cell-cycle inhibitors. In addition, 
BMI1 was shown to inhibit cancer stem-cell functions.
The proposed protocol was proven to be reproducible and 
scalable, although some issues will be updated at the end of 
the clinical trial, as the optimal specification limits for the 
potency assay and the outcome of follow-up investigations.
The non-clinical testing strategy included an evaluation of 
the previous studies in conjunction with the proposed non-
clinical human tissue testing for safety assessments, since 
suitable animal models showed significant inconsistencies 
with human cell behaviors, under these culture conditions.
The combined data from human cell characterization, 
stem-cell maintenance, standardization, and comparison 
with similar products indicate that the proposed treatment 
could represent an efficacious approach for the restoration 
of urethra, to address failed hypospadias cases.
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